Chinese COPD innovative medicine! AstraZeneca's innovative triple inhaler budigor is officially launched for COPD maintenance treatment!

January 13, 2020 / BIOON / -- AstraZeneca recently announced that the triple new drug budigor inhaled aerosol of copf was officially launched in China Budesonide inhaled aerosol adopts innovative co suspension drug delivery technology, combined delivery of budesonide (inhaled glucocorticoid ICs) / glulammonium bromide (long-acting anticholinergic drug Lama) / formoterol fumarate (long-acting β 2 receptor agonist Laba) three drug components, providing an important treatment option for patients with chronic obstructive pulmonary disease in stable period In China, budegfu inhalation aerosol was officially approved by the National Drug Administration (nmpa) in December 2019 for maintenance treatment of patients with chronic obstructive pulmonary disease As a triple inhalation innovative drug for COPD treatment, budegfu inhalation aerosol was approved earlier than that in Europe and America, making China the second country in the world to approve the drug In June 2019, the drug was first sold in Japan under the brand name breztri aerosphere (pt010) as a triple therapy to relieve symptoms of COPD Compared with the dual drugs, the triple inhaled Budesonide aerosol and "black technology" can help the management of COPD, and the inhaled Budesonide aerosol can bring multiple benefits to COPD patients The results of Kronos study published in the Lancet journal of respiratory medicine showed that compared with the treatment of double bronchodilators, budigfurt inhalation aerosol can significantly reduce the rate of moderate to severe acute exacerbations by 52%, and prolong the time to reach the first moderate to severe acute exacerbations At the same time, the drug has a rapid and sustainable improvement of lung function, and has good safety Wang Chen, director of the national respiratory clinical research center, director of the respiratory center of China Japan Hospital, and China's leading researcher of Kronos phase III research, said: "reducing the disease burden of COPD is a priority issue in the field of public health in China Kronos studies have shown that inhaled budesonide can improve lung function rapidly and continuously, and reduce the risk of exacerbation in moderate to severe patients, compared with dual therapy Triple therapy will play a very important role in dealing with the challenges of COPD, especially acute exacerbation in China " Professor Kang Jian, vice president of the respiratory branch of the Chinese Medical Association and director of the respiratory disease Research Institute of the First Affiliated Hospital of China Medical University, stressed: "inhalation therapy is the first choice for the treatment of COPD The newly launched triple inhalation preparation contains three drugs, which can deliver the drug particles of appropriate size to the small airway and achieve the high deposition of drugs in the small airway For the patients who used the combination of two drugs in the past with poor effect, repeated acute aggravation, moderate and severe COPD, the combination of three drugs can be selected " In our country, the patients with COPD are mostly middle-aged and elderly people The use of inhaled drugs is often limited by some factors, such as the lack of strength of inhaled drugs in the lung, the inconvenience of using and carrying devices, which affect the efficacy of maintenance treatment After more than 50 years of exploration, the inhaler of COPD has been updated and iterated several times Professor Chen Rongchang, leader of the group of COPD and director of Shenzhen Institute of respiratory diseases, respiratory branch of Chinese Medical Association, said: "COPD is a disease with small airway as the main lesion, and the inhalation device is the key factor affecting the treatment The new generation of the device, which adopts the co suspension technology, makes up for the shortcomings of the traditional DPI and PMDI devices, helps patients inhale more air, increases patients' deep inspiratory capacity, and improves their breathing and activity In addition, the prognosis of patients with COPD treated with a single inhalation device is better than that with a combination of multiple inhalation devices, which is also beneficial to the compliance of patients " Chronic obstructive pulmonary disease is the third leading cause of death Standardized treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease is one of the most common chronic respiratory diseases in China, with nearly 100 million patients Professor Shen Huahao, director of the respiratory medicine branch of the Chinese Medical Association, and professor of Respiratory Diseases Research Institute of Zhejiang University, said: "there is one chronic obstructive pulmonary disease patient among every 7 people aged 40 and over in China The incidence rate of chronic obstructive pulmonary disease is 8.6% among people aged 20 and over COPD is a "silent killer" There are no symptoms in the early stage and it is easy to be ignored Once there are symptoms, lung function may have lost about 50%, which is very harmful Early detection and early treatment are very important " Patients with COPD often have sudden aggravation of symptoms, leading to hospitalization, which is a typical case of acute aggravation of patients As for acute exacerbation, Professor Sun Yongchang, member of the Standing Committee and secretary-general of the respiratory branch of the Chinese Medical Association and vice leader of the chronic obstructive pulmonary disease group, explained: "the frequency of acute exacerbation in Chinese patients is actually very frequent, with an average of 2 times of acute exacerbation in one year However, many patients with COPD have insufficient understanding of acute exacerbation It is often thought that it is just a small cold, in fact, the acute aggravation will cause very serious consequences, including irreversible damage to lung function, increased risk of cardiovascular disease, impact on quality of life, increased risk of hospitalization and treatment costs, etc What's more, acute exacerbation also greatly increases the risk of death In order to prevent the acute aggravation, the patients must pay attention to the standard treatment in the stable period " Professor Zhou Xin, vice chairman of Respiratory Society of Chinese Medical Association and leader of respiratory and critical medical science department of the first people's Hospital Affiliated to Shanghai Jiaotong University, stressed: "winter is a season with high incidence of acute exacerbation of COPD, so special attention should be paid in winter, and a variety of measures can be taken to prevent the acute exacerbation of COPD, such as quitting smoking, vaccinating, etc In fact, COPD, like diabetes and hypertension, are chronic diseases that need long-term treatment Only by adhering to standardized treatment can we effectively prevent and improve cough and asthma symptoms, reduce the frequency and severity of acute attacks, and prevent or delay the deterioration of lung function " Challenges and opportunities coexist Many parties work together to prevent and control chronic obstructive pulmonary disease (COPD) in China The death rate of COPD patients in China is the third leading cause of death after the sum of cardiovascular and cerebrovascular diseases and cancer For 100 million patients with COPD in China, both the continuous treatment cost of drug treatment and the high medical cost caused by repeated hospitalization caused by acute aggravation have brought heavy burden to patients and families At the same time, COPD has the characteristics of high morbidity, high disability, high mortality and high disease burden, which makes it a serious public health problem There are many challenges in the management of COPD in China The prevention and control of COPD needs the joint efforts of the government, society, doctors and patients to actively respond to the challenges and realize the optimal management of COPD Chen penggen, general manager of China's respiratory, inflammatory and autoimmune Business Department of AstraZeneca, said: "budegfu aerosol provides important treatment options for patients with chronic obstructive pulmonary disease, and we expect innovative drugs and devices to bring good disease control to patients with chronic obstructive pulmonary disease and reduce the risk of acute exacerbation In the face of China's large number of patients with COPD who need innovative treatment and management programs, AstraZeneca will continue to focus on patients and continue to work in the field of breathing for the benefit of patients " On budighoff inhalation aerosol Budesonide inhaler is a kind of fixed dose three in one inhaler, which uses innovative and innovative device to deliver three drug components of budesonide (inhaled glucocorticoid ICs) / long-acting anticholinergic agent Lama / fumaric acid formoterol (long-acting β 2-receptor agonist Laba), providing an important treatment option for the appropriate patients with chronic obstructive pulmonary disease, and also for the patients It provides a convenient and innovative way to take medicine In January 2019, budigfurt inhalation aerosol was qualified for priority review In December 2019, China National Drug Administration officially approved budigfurt inhalation aerosol for maintenance treatment of patients with chronic obstructive pulmonary disease Budigfurt inhalation aerosol is equipped with an innovative patency device, and the co suspension drug loading technology is applied The innovative technology enables the drugs to reach the large and small airway of the lung and achieve a high deposition rate of the lung At the same time, the dosage of each spray is stable, so that the right dosage can be delivered from the first to the last inhalation Chronic obstructive pulmonary disease (COPD) and acute exacerbation of COPD have the characteristics of high morbidity, high disability, high mortality and high disease burden According to the latest epidemiological survey data, the prevalence rate of COPD is 13.7% in the population aged 40 and over in China, and the number of patients is close to 100 million However, according to the data of the World Health Organization, the mortality rate of COPD in China is the highest in all countries, and it has become the third leading cause of death for residents The overall burden of disease in China is the second and higher than the global level Acute exacerbation of COPD is one of the manifestations of the rapid deterioration of the disease Acute exacerbation is very destructive to COPD patients, which leads to irreversible damage of lung function and greatly increases the risk of death Source: AstraZeneca